Search Within

Ariela Noy

Formats
  1. Meeting Abstract (204)
  2. Journal Article (143)
  3. Research Letter (10)
  4. Book Section (6)
  5. Review (6)
  6. Editorial (2)
  7. Correspondence (1)
  8. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (373)
  2. Department of Medicine (373)
  3. Hematologic Malignancies, Division of (373)
  4. Lymphoma (373)
  5. Survivorship Research (163)
  6. Population Sciences Research Program (150)

More Groups

People
  1. Andrew Zelenetz (187)
  2. Paul Hamlin (144)
  3. David Straus (139)
  4. Steven Horwitz (138)
  5. Maria Palomba (131)
  6. Alison Moskowitz (118)

More People

Years
  1. 2025 (9)
  2. 2024 (27)
  3. 2023 (24)
  4. 2022 (15)
  5. 2021 (30)
  6. 2020 (26)

More Years

Publications
  1. Blood (166)
  2. Journal of Clinical Oncology (42)
  3. Hematological Oncology (19)
  4. Leukemia and Lymphoma (15)
  5. Blood Advances (13)
  6. Annals of Oncology (12)

More Publications

Publishers
  1. American Society of Hematology (179)
  2. American Society of Clinical Oncology (43)
  3. Wiley Blackwell (23)
  4. Elsevier Inc. (21)
  5. Taylor & Francis Group (15)
  6. Ferrata Storti Foundation (12)

More Publishers

Results (373)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): Phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
    Journal Article

    Rubinstein, P. G.; Moore, P. C.; Bimali, M.; Lee, J. Y.; Rudek, M. A.; Chadburn, A.; Ratner, L.; Henry, D. H.; Cesarman, E.; DeMarco, C. E.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Daratumumab and EPOCH for HIV+/‐ plasmablastic lymphoma: A feasibility study of the AIDS Malignancy Consortium (AMC 105)
    Meeting Abstract

    Noy, A.; Barta, S. K.; Tan, C. R.; Kwon, D.; Baiocchi, R.; Rubinstein, P.; Ambinder, R.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Predictors of survival in patients with MALT lymphoma: A retrospective, case-control study
    Review

    Qi, S.; Liu, X.; Noy, A.; Lee, J.; Teckie, S.; Hajj, C.; Joffe, E.; Imber, B. S.; Yahalom, J.
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save